Afatinib and gefitinib: a direct comparison

During the last decade, scientific literature had already reported data on frequency and characteristics of EGFR mutations among patients with non-small-cell lung cancer (NSCLC) and their response to tyrosine kinase inhibitors (TKIs) (1). Actually EGFR mutation-positive NSCLC is a well-defined molecular type of lung cancer with specific first-line treatment options.